drugset
drugset / Trial / NCT02202759

A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

NCT02202759 ↗

Phase 2 Terminated 38 enrolled Millennium Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.

Timeline

Start
2014-08-04
Primary completion
2016-01-15
Completion
2016-01-15

Outcome

Outcome not reported

Stopped (Business): “Business Decision, No Safety or Efficacy Concerns”

Drugs

EvaluationDrugModalityDoseRoute
Subject INDUSATUMAB VEDOTIN Unknown 1.8 mg/kg Intravenous

Indications

gastric adenocarcinoma gastroesophageal junction adenocarcinoma